forpressrelease Mail to a Friend
forpressrelease Rate forpressrelease forpressrelease forpressrelease forpressrelease forpressrelease 

Universal Flu Vaccine Stimulates Global Influenza Vaccine Market



2024-03-13 06:18:37 Business

forpressrelease
346


According to a new research report by RNCOS entitled, ?Global Influenza Vaccine Market Outlook 2022?, the influenza vaccine has gained huge popularity in past couple of years due to frequent life threatening influenza outbreaks. The major growth drivers of the industry are growing healthcare expenditure, increasing awareness, tough competition, rising disposable income and huge government support.

The universal flu vaccine is sole vaccine that protects against all the types of influenza viruses prevailing in an environment. The scientist, worldwide, are working on developing a universal vaccine so that people do not have to get vaccinated for each virus, this will not only increase the vaccination coverage ratio but also lead to the development of a nation.

It takes 6 months to produce a vaccine matched to a new influenza virus. A universal vaccine, on the contrary, could be used immediately and could provide some protection against a newly emerging influenza virus that connoisseurs had not identified. A universal vaccine would abate the severity of disease, speed up the ability of the body to fight with the virus, and reduce the fatality rate of infections until a specific vaccine against that virus is available.

The consumer mindset has also changed in the past couple of years. They have started getting vaccinated, rather than sticking to medicines for each type of flu and this has resulted in increased influenza vaccine demand. The healthcare services in developed countries are provided at such a high price that most of the people cannot afford them, so they prefer to take precautionary measures rather than paying hefty amount at the time of outbreak.

The companies such as Vaccitech and Inovio have started developing universal vaccines using different technologies to get rid of multiple vaccines. Vaccitech is currently planning a phase IIb in which 1500 -patient trial is scheduled to begin later in 2016.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM833.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm




ABOUT RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Company :-RNCOS E-Services Pvt. Ltd.

User :- Shushmul Maheshwari

Email :-press@rncos.com

Phone :-91-120-4224-700

Mobile:- -

Url :- http://www.rncos.com






Related Post

Advertisement

To ensure stability and reachability of your applications at all times, remote DDoS protection can keep your hosting services online

Sponsored News Release